Compare Equinor ASA (EQNR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs ResMed Inc. — how do they compare? Equinor ASA trades at $43.02 (market cap $101.62B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: Equinor ASA is far larger — about 3.2× ResMed Inc.'s market cap, and Equinor ASA pays the higher dividend (3.63%). Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and ResMed Inc. for 51 Days on average.
| EQNR | RMD | |
|---|---|---|
Market Cap | $101.62B | $31.89B |
Volume | 4,991,782 | 618,314 |
Sector | Energy | Health |
52-Week High | $45.75 | $277.88 |
52-Week Low | $22.41 | $182.82 |
Typical Hold Time | 59 Days | 51 Days |
Enterprise Value | $110.31B | $31.24B |
Dividend Yield | 3.63% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $43.01, up 3.36% today, with strong technical momentum indicated by bullish moving averages. The stock shows attractive valuation metrics with a P/E of 11.63 and EV/EBITDA of 2.39, while recent earnings beat expectations in two of the last three quarters. The company maintains solid profitability with 21.32% ROE and continues strategic expansion in LNG markets through new supply agreements.
EQNR presents compelling value with significant upside to the $87.50 consensus price target, though investors face risks from volatile energy prices and declining profit margins. The company's LNG expansion strategy and share buyback program provide catalysts, but execution risks and commodity price sensitivity require careful monitoring.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
